Cost-effectiveness analysis of first-line serplulimab combined with chemotherapy for extensive-stage small cell lung cancer

BACKGROUND: For patients with extensive-stage small cell lung cancer (ES-SCLC), serplulimab plus chemotherapy is beneficial as the first-line treatment. It is uncertain whether serplulimab plus chemotherapy will be more cost-effective. The aim of this study was to evaluate from the perspective of th...

Descripción completa

Detalles Bibliográficos
Autores principales: Liang, Xueyan, Chen, Xiaoyu, Li, Huijuan, Li, Yan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Public Health
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10505963/
https://www.ncbi.nlm.nih.gov/pubmed/37727602
http://dx.doi.org/10.3389/fpubh.2023.1156427

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10505963/
https://www.ncbi.nlm.nih.gov/pubmed/37727602
http://dx.doi.org/10.3389/fpubh.2023.1156427

Ejemplares similares